The top five predicted drugs that might upregulate MEG3 (Table 4) include RN-1734, a TRPV4 antagonist that was shown to reduce demyelination in central nervous system diseases as well as inhibit glial activation and IL-β and TNF-α production (111). Here, TRPV4 is linked to central nervous system disorder.